Prostate Cancer · Localised Disease Cambridge Prognostic GroupsCPG 1–5 at a glance A fast-reference guide for busy clinicians — risk stratification, staging patterns, and treatment intent for localised prostate cancer CPG 1 — Low risk CPG 2 — Intermediate favourable CPG 3 — Intermediate unfavourable CPG 4 — High risk CPG 5 — Very high…
Clinical Pharmacology · Oncology & Cardiology Interface
Treatment selection in advanced prostate cancer just got sharper. Lutetium-177-PSMA-617 (Pluvicto®) has changed the landscape for metastatic castration-resistant prostate cancer (mCRPC). But with high costs, potential toxicity, and variable responses, the million-dollar question remains: Who will actually benefit? New data published in eClinicalMedicine (October 2024) gives us the first high-quality, validated nomograms to answer this…